PA8485701A1 - Derivados de indol - Google Patents

Derivados de indol

Info

Publication number
PA8485701A1
PA8485701A1 PA19998485701A PA8485701A PA8485701A1 PA 8485701 A1 PA8485701 A1 PA 8485701A1 PA 19998485701 A PA19998485701 A PA 19998485701A PA 8485701 A PA8485701 A PA 8485701A PA 8485701 A1 PA8485701 A1 PA 8485701A1
Authority
PA
Panama
Prior art keywords
indol
derivatives
monohydrate
procedures
preparing
Prior art date
Application number
PA19998485701A
Other languages
English (en)
Inventor
Ronald James Ogilvie
Christopher Ian Dallman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8485701A1 publication Critical patent/PA8485701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

La presente invención proporciona bromhidrato de eletriptán monohidratado de formula (I) junto con procedimientos para preparar dicho monohidrato, usos del mismo y composiciones que lo contienen.
PA19998485701A 1998-11-27 1999-11-18 Derivados de indol PA8485701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives

Publications (1)

Publication Number Publication Date
PA8485701A1 true PA8485701A1 (es) 2000-09-29

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998485701A PA8485701A1 (es) 1998-11-27 1999-11-18 Derivados de indol

Country Status (53)

Country Link
US (2) US20020013358A1 (es)
EP (1) EP1135381B1 (es)
JP (1) JP3777094B2 (es)
KR (1) KR100413739B1 (es)
CN (1) CN1131860C (es)
AP (1) AP2001002149A0 (es)
AR (1) AR024232A1 (es)
AT (1) ATE273300T1 (es)
AU (1) AU754731B2 (es)
BG (1) BG64706B1 (es)
BR (1) BR9915692A (es)
CA (1) CA2352392C (es)
CO (1) CO5150178A1 (es)
CR (1) CR6325A (es)
CU (1) CU23269A3 (es)
CZ (1) CZ295472B6 (es)
DE (1) DE69919388T2 (es)
DK (1) DK1135381T3 (es)
DZ (1) DZ2948A1 (es)
EA (1) EA003551B1 (es)
EE (1) EE04914B1 (es)
ES (1) ES2224701T3 (es)
GB (1) GB9825988D0 (es)
GC (1) GC0000113A (es)
GE (1) GEP20043183B (es)
GT (1) GT199900202A (es)
HK (1) HK1042898B (es)
HN (1) HN1999000196A (es)
HR (1) HRP20010398B1 (es)
HU (1) HUP0105308A3 (es)
ID (1) ID28802A (es)
IL (1) IL141663A (es)
IS (1) IS2238B (es)
MA (1) MA26708A1 (es)
MY (1) MY124078A (es)
NO (1) NO320798B1 (es)
NZ (1) NZ510055A (es)
OA (1) OA11671A (es)
PA (1) PA8485701A1 (es)
PE (1) PE20001299A1 (es)
PL (1) PL194503B1 (es)
PT (1) PT1135381E (es)
RS (1) RS50002B (es)
SI (1) SI1135381T1 (es)
SK (1) SK285774B6 (es)
SV (1) SV1999000204A (es)
TN (1) TNSN99221A1 (es)
TR (1) TR200101493T2 (es)
TW (1) TWI246512B (es)
UA (1) UA68402C2 (es)
UY (2) UY25823A1 (es)
WO (1) WO2000032589A1 (es)
ZA (1) ZA200102681B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
WO2008150500A1 (en) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) * 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
RO111767B1 (ro) 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
TR199903332T2 (xx) 1997-07-03 2000-09-21 Pfizer Inc. Eletriptan hemis�lfat ve kafein i�eren farmas�tikal bile�ikler.

Also Published As

Publication number Publication date
ATE273300T1 (de) 2004-08-15
CO5150178A1 (es) 2002-04-29
TNSN99221A1 (fr) 2005-11-10
GT199900202A (es) 2001-05-19
CN1131860C (zh) 2003-12-24
HRP20010398B1 (en) 2004-12-31
SV1999000204A (es) 2000-10-16
ES2224701T3 (es) 2005-03-01
EE200100285A (et) 2002-08-15
WO2000032589A1 (en) 2000-06-08
CA2352392C (en) 2006-01-24
IS2238B (is) 2007-05-15
DZ2948A1 (fr) 2004-03-15
UA68402C2 (en) 2004-08-16
CU23269A3 (es) 2008-04-09
JP2002531449A (ja) 2002-09-24
AR024232A1 (es) 2002-09-25
NO320798B1 (no) 2006-01-30
ID28802A (id) 2001-07-05
EA200100297A1 (ru) 2001-08-27
IL141663A (en) 2004-05-12
BG64706B1 (bg) 2005-12-30
DE69919388D1 (de) 2004-09-16
PL194503B1 (pl) 2007-06-29
MY124078A (en) 2006-06-30
PL347928A1 (en) 2002-04-22
SK285774B6 (sk) 2007-08-02
MA26708A1 (fr) 2004-12-20
GEP20043183B (en) 2004-02-25
AU754731B2 (en) 2002-11-21
GB9825988D0 (en) 1999-01-20
HUP0105308A3 (en) 2003-01-28
RS50002B (sr) 2008-09-29
ZA200102681B (en) 2002-07-02
EP1135381A1 (en) 2001-09-26
HK1042898A1 (en) 2002-08-30
KR20010080594A (ko) 2001-08-22
TR200101493T2 (tr) 2002-02-21
OA11671A (en) 2005-01-12
KR100413739B1 (ko) 2004-01-03
TWI246512B (en) 2006-01-01
SI1135381T1 (en) 2004-10-31
HN1999000196A (es) 2005-11-26
CZ295472B6 (cs) 2005-08-17
CA2352392A1 (en) 2000-06-08
HK1042898B (zh) 2004-10-08
NO20012584L (no) 2001-07-27
BR9915692A (pt) 2001-08-14
BG105539A (en) 2001-12-29
PE20001299A1 (es) 2000-12-01
CZ20011839A3 (cs) 2001-10-17
DK1135381T3 (da) 2004-11-15
UY25825A1 (es) 2000-08-21
IS5868A (is) 2001-02-27
NZ510055A (en) 2004-11-26
HUP0105308A2 (hu) 2002-05-29
IL141663A0 (en) 2002-03-10
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
DE69919388T2 (de) 2005-09-29
PT1135381E (pt) 2004-10-29
NO20012584D0 (no) 2001-05-25
JP3777094B2 (ja) 2006-05-24
AU6225399A (en) 2000-06-19
YU18801A (sh) 2003-07-07
UY25823A1 (es) 2001-08-27
EE04914B1 (et) 2007-10-15
US7238723B2 (en) 2007-07-03
EA003551B1 (ru) 2003-06-26
HRP20010398A2 (en) 2002-06-30
US20050131237A1 (en) 2005-06-16
CR6325A (es) 2008-07-02
SK6992001A3 (en) 2002-01-07
AP2001002149A0 (en) 2001-06-30
CN1328554A (zh) 2001-12-26
US20020013358A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
BR9914526A (pt) Derivados de adenina
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
DK0657458T3 (da) Inhibitorer af proteinkinase-C
AP9901534A0 (en) Pharmaceutical formulations.
PA8485701A1 (es) Derivados de indol
ATE269079T1 (de) Stabilisierung pharmazeutischer zusammensetzungen durch besonderen einsatz eines antioxidans
ES2195970T3 (es) L-ribavirina y usos de la misma.
PE14199A1 (es) Agonistas de 5-ht1f
AR024138A1 (es) Inhibidores de la proliferacion celular
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BR0207543A (pt) Quinolinona tricìclica e quinolina tricìclica como compostos moduladores de receptor de androgênio
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
CO4940435A1 (es) Sal de hemisulfato del (1s,4r)-cis-4-[2-amino-6- (ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol o un solvato del mismo
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
ECSP993238A (es) Derivados de indol
ATE418613T1 (de) Antimikrobielle zusammensetzungen
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
AR015147A1 (es) Compuestos de 1-bis-trifluorometilbenzoil-2-indolilmetil-4-bencilamino-metil-piperazina, medicamentos que los contienen, y procedimiento para supreparacion
AR021502A1 (es) Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso
TR200100316T2 (tr) Yeni benz [f] indollerin üretim yöntemleri, ilaç olarak kullanımları
ECSP982434A (es) Quinoxalinadionas